Our Platform
Lab‑friendly platform for immune‑based platelet function testing
PlateletDiagnostics is built on a next‑generation platelet signaling platform that measures phosphorylation of dynamin‑related protein 1 (Drp1), a highly abundant mitochondrial GTPase in human platelets.
By quantifying Drp1 phosphorylation at two sites—Ser616, reporting activation through p38 MAPK downstream of GPCR and ITAM/hemITAM receptors, and Ser637, reporting inhibitory signaling through PKA/PKG and cyclic nucleotide pathways—the assay captures both pathologic platelet activation and pharmacologic platelet inhibition within a single, immune‑based technology.
This dual‑site design transforms complex intracellular signaling into a robust chemiluminescent ELISA readout that fits seamlessly into standard clinical laboratory workflows.
Source: Barrios et al.; Blood; 2026. https://doi.org/10.1182/blood.2025031772
As a platform, Drp1 phosphorylation enables a true functional assessment of HIT and related immune thrombocytopenic states by directly measuring FcγRIIA‑driven platelet activation in response to patient plasma and heparin. In parallel, the same backbone supports high‑performance monitoring of antiplatelet therapeutics, including aspirin and P2Y12 inhibitors, where Drp1 readouts have demonstrated strong concordance with incumbent methods such as light transmission aggregometry and cartridge‑based systems while offering improved dynamic range, stability, and scalability.
Because all of these applications share the same capture/detection reagents, instrumentation, and data architecture, PlateletDiagnostics can deliver a growing test menu—from HIT functional diagnostics to comprehensive antiplatelet therapy monitoring—on one unified technology platform.
PlateletDiagnostics can deliver a growing test menu—from HIT functional diagnostics to comprehensive antiplatelet therapy monitoring—on one unified technology platform.
This strategy positions PlateletDiagnostics as more than a single assay: it is a configurable, lab‑friendly platform for immune‑based platelet function testing. Central labs can deploy it in high‑throughput ELISA formats for batched HIT and antiplatelet testing, while selected indications can be extended into rapid or decentralized formats without changing the underlying biology or analytical framework. For clinicians, this means a consistent, quantitative view of platelet behavior across immune‑mediated activation and therapeutic inhibition; for investors, it creates a scalable product family and a defensible biomarker franchise anchored in Drp1 phosphorylation.
Contact Us
For investor or media relations, please feel free to reach out to us.